Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam. The present invention further relates to a therapeutically active agent for use in treating a retina disorder in a human, wherein the therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina. The present invention also relates to an eye ultrasound delivery device that may be used to treat a retina disorder.

The present disclosure relates to, inter alia, a method for treating a tumor by intratumorally delivering an effective amount of a composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretable vaccine protein, and a second nucleotide sequence encoding a T cell costimulatory fusion protein.

Enhanced delivery of compositions for treatment of skin tissue with photoactive plasmonic nanoparticles and light, with embodiments relating to delivery devices using, for example, ultrasound. Treatments are useful for cosmetic, diagnostic and therapeutic applications.

Provided herein are various gas-filled particles having a stimuli-responsive shell encapsulating the gas. The stimuli-responsive shell comprises one or more release triggers. Compositions for medical or non-medical applications, methods of use and treatment, and methods of preparation are also described.

The invention describes particles having a polypeptide shell. The polypeptide shell comprises at least one immunomodulatory polypeptide. Particles may be ultrasound-responsive particles, providing the ability to administer particles trandermally, or deliver particles to selected sites by use of ultrasound. Administration of the particles generates immunologic response to the polypeptide in the shell of the particle. The particles are therefore useful in methods of immunotherapy.

Disclosed herein are electrotransfer (ET) methods for delivering therapeutic agents to tumors. Also disclosed are methods of using the ET methods for differential delivery of an agent to more than one tissue. For example, the ET methods can be used to deliver soluble peptides of PD1 to tumor tissue to block normal PD1-PDL1 binding while separately using the ET methods to deliver PD1 or PDL1 antigen to another tissue, such as skin or muscle, to induce systemic and polyclonal checkpoint inhibitor antibodies.

Systems and methods of stimulating or activating fluids for use in wound treatment systems.

Disclosed includes an ophthalmic composition for treating an eye condition and a method for treating an eye condition. The composition comprising a DNA repair enzyme, which can be administered to an eye of the patient in need. Some of the eye conditions that can be treated include glaucoma, optic neuritis, retinopathy, cataracts, macular degeneration, corneal abrasions or ulcers, melanomas, basal cell carcinomas, and other malignant or benign tumors.

Provided herein is an immunogenic composition comprising a synthetic consensus FAP antigen. Also disclosed herein is a method of treating or preventing a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.